Kidney cancer drug rejected10th July 2007
A charity says a ruling not to approve a kidney cancer drug for use in the NHS in Scotland is a ‚Äúdeath sentence‚Ä? to hundreds of patients.
The Scottish Medicines Consortium said the benefits of Sutent (Sunitinib) did not yet justify its high cost, even though the James Whale Fund said the drug is the most effective first-line treatment for advanced kidney cancer. Manufacturer Pfizer plans to resubmit a proposal to the SMC based on new evidence. A decision on the drug for use in England has yet to be made by the National Institute for Health and Clinical Excellence.
Share this page
There are no comments for this article, be the first to comment!
Post your comment
Only registered users can comment. Fill in your e-mail address for quick registration.
Title: Kidney cancer drug rejected
Author: Mark Nicholls
Article Id: 3409
Date Added: 10th Jul 2007